WELCOME!

About 70,000 adults and children in the UK have Polycystic Kidney Disease or PKD - life-threatening inherited conditions that can cause renal (kidney) failure and affect other organs in the body.

We support those affected, their families and carers. We raise awareness and fund research.

Find out more about PKD.

SUPPORT LINE

0300 111 1234

Welcome to the PKD Charity

Find out more about PKD

ADPKD - AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE - is the world’s most common inherited kidney disease, in which fluid-filled cysts develop, multiply and grow in both kidneys. Other organs, such as the liver and brain, may be affected. Between 1 in 400 and 1 in 1000 people worldwide - about 12.5 million - have ADPKD. Over half of those affected will have kidney failure by the time they are 60 years old. Many will experience regular pain, disabiity and anxiety throughout life. If someone has ADPKD, there is a 1 in 2 (50 percent) likelihood that the disease will pass to each child born.

Read more about ADPKD.

ARPKD - AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE - is a rare disease that affects the kidneys and liver. It occurs in about one in every 20,000 live births in the UK. ARPKD is a severe disease. Sadly, about one baby in three with ARPKD dies from breathing problems during the first four weeks after birth and some will die during pregnancy. However, 8 to 9 in ten babies (80-90 per cent) who survive the first four weeks of life are still alive at five years old. Encouragingly, a good number of children  now survive into adulthood and are able to live full and productive lives.

Read more about ARPKD.

PrintEmail

Latest News & Events

Spring Ball raises £2,000

March 2016

A Spring Ball held at Tern Hill Hall, Shropshire Saturday 5th March 2016 raised almost £2,000 for the PKD Charity.

Read more ...

Awards for All Peer Support Pilot Grant Awarded

February 2016

PKD Charity receives Awards for All Grants to Pilot 1-Year Telephone Befriending & Peer Support Project

Read more ...

SMC Accepts Tolvaptan (JINARC®) to Treat ADPKD in Scotland

January 2016

11 January 2016:The Polycystic Kidney Disease (PKD) Charity is delighted that the Scottish Medicines Consortium (SMC) Committee has, after careful consideration of all the evidence, decided to accept tolvaptan (brand name: JINARC®) for routine use by NHS Scotland.

Read more ...

Latest Research

Grant to investigate blood pressure in children and young people with ADPKD

The PKD Charity has awarded £10,000 to UCL Institute of Child Health/Great Ormond St Hospital for a study investigating the optimal bood pressure level in children and young people with ADPKD (Autosomal Dominant Polycystic Kidney Disease).

Read more ...

Development of clinical biomarkers of ADPKD progression

Final report from the investigators: Our hypothesis is that the proteins contained in the small vesicles (called exosomes) contained in the urine of ADPKD (Autosomal Dominant Polycystic Kidney Disease) patients reflect the disease stage and severity and can be used to identify biomarkers and evaluate risk of progression.

Read more ...

First-ever grant from the PKD Charity for ARPKD Research

The PKD Charity has awarded £10,000 to Dr Evi Goggolidou of Kingston University for a study on a gene which is believed to influence the development and progression of Autosomal Recessive Polycystic Kidney Disease (ARPKD).

Read more ...

Latest Tweets

PKD Charity is a Member of